Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E25.17 EPS (ttm)6.35 Insider Own0.10% Shs Outstand760.67M Perf Week5.19%
Market Cap121.56B Forward P/E17.21 EPS next Y9.29 Insider Trans-2.19% Shs Float759.85M Perf Month-2.87%
Income4.89B PEG2.22 EPS next Q2.05 Inst Own83.10% Short Float1.06% Perf Quarter11.68%
Sales19.74B P/S6.16 EPS this Y20.30% Inst Trans0.19% Short Ratio2.13 Perf Half Y31.85%
Book/sh33.28 P/B4.80 EPS next Y8.08% ROA7.10% Target Price172.45 Perf Year31.80%
Cash/sh36.91 P/C4.33 EPS next 5Y11.33% ROE20.70% 52W Range106.69 - 173.14 Perf YTD0.33%
Dividend3.16 P/FCF22.77 EPS past 5Y12.00% ROI10.50% 52W High-6.87% Beta0.55
Dividend %1.98% Quick Ratio3.90 Sales past 5Y4.50% Gross Margin80.40% 52W Low51.14% ATR4.97
Employees20000 Current Ratio4.20 Sales Q/Q6.00% Oper. Margin34.90% RSI (14)53.79 Volatility2.83% 3.18%
OptionableYes Debt/Eq1.30 EPS Q/Q-10.10% Profit Margin24.70% Rel Volume0.86 Prev Close159.81
ShortableYes LT Debt/Eq1.20 EarningsJan 27 AMC Payout35.70% Avg Volume3.77M Price161.25
Recom2.40 SMA202.04% SMA50-0.33% SMA20018.97% Volume919,171 Change0.90%
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jan-24-13Reiterated UBS Buy $96 → $98
Sep-12-12Downgrade Robert W. Baird Outperform → Neutral $84
Sep-10-12Upgrade UBS Neutral → Buy $80 → $96
Jan-26-15 08:02AM  Can CAR-T Therapy Live Up To The Biotech IPO Hype? at Investor's Business Daily
06:53AM  Regeneron vaults ahead of Amgen in race to market cholesterol drug at Fortune
02:46AM  Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race at Forbes
Jan-23-15 06:25PM  Will Amgen (AMGN) Keep the Earnings Streak Alive in 4Q? - Analyst Blog Zacks
04:20PM  Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog Zacks
06:15AM  Up to Speed: Death of Saudi king moves needle on oil prices (Video) at American City Business Journals
Jan-22-15 07:00PM  UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Zacks
06:35PM  Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog Zacks
06:00PM  BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Zacks
05:40PM  Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Zacks
04:10PM  Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Zacks
04:01PM  Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results PR Newswire
02:06PM  An easier way to understand the pharma industry Market Realist
Jan-21-15 06:13PM  Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst Blog Zacks
06:08PM  Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst Blog Zacks
05:00PM  Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog Zacks
12:50PM  Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog Zacks
11:02AM  Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog Zacks
09:30AM  Drug companies find common ground over Colorado's 'biosimilars' legislation at American City Business Journals
Jan-20-15 06:03PM  Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - Analyst Blog Zacks
05:00PM  Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Zacks
03:30PM  Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst Blog Zacks
11:55AM  J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst Blog Zacks
10:15AM  Three Market Leading Healthcare Picks at Forbes
07:41AM  Regeneron CEO: Choice, not price best for patients CNBC
Jan-19-15 06:35PM  AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst Blog Zacks
07:10AM  'Biosimilars' law returns to Colorado Legislature; would allow generics to be swapped for biotech drugs at American City Business Journals
Jan-16-15 04:45PM  ZIOPHARM, Intrexon Ink CAR T Deal with MD Anderson - Analyst Blog Zacks
04:00PM  Amgen (AMGN) Reveals Mixed Results from Vectibix Studies - Analyst Blog Zacks
11:10AM  Hospira Submits Retacrit Regulatory Application to the FDA - Analyst Blog Zacks
09:30AM  Amgen, Rio Tinto, Intel, IBM and Cisco highlighted as Zacks Bull and Bear of the Day - Press Releases Zacks
01:00AM  Bull of the Day: Amgen (AMGN) - Bull of the Day Zacks
Jan-15-15 04:01PM  Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer PR Newswire
10:30AM  AstraZeneca Announces Encouraging Data from Brilinta Study - Analyst Blog Zacks
Jan-14-15 03:40PM  Amgen Maintains 2015 View, Expects Several Drug Launches - Analyst Blog Zacks
02:39PM  Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog Zacks
Jan-13-15 04:28PM  Express Scripts sees opportunity to lower cancer treatment cost Reuters
01:23PM  The Poster Child For Risk and Reward Yahoo Finance Blogs
Jan-12-15 04:01PM  Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome PR Newswire
10:15AM  Analyzing Eli Lilly's drug pipeline CNBC
Jan-09-15 03:42PM  Regeneron Jumps On Favorable Cholesterol Drug Report at Investor's Business Daily
01:58PM  Regeneron Can Generate 25% Upside for Investors at Barrons.com
10:37AM  Sanofi, Regeneron cholesterol drug also effective in monthly doses Reuters
Jan-08-15 04:15PM  FDA panel OKs copy of Amgens Neupogen cancer drug at American City Business Journals
04:15PM  Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
03:43PM  Does 23andMe Deal Mean Medical Centers Are Sitting On Data Worth Millions? at Forbes
01:31PM  'Dirty' discovery in antibiotics CNBC
01:28PM  FDA paves way for cheaper cancer drug copies CNBC
08:02AM  5 Potential Blockbuster Drugs Set To Launch In 2015 at Investor's Business Daily
Jan-07-15 05:06PM  Why The FDA Panel's Nod To Sandoz's Filgrastim (Zarzio) Is Good News For Patients at Forbes
04:11PM  Novartis Biosimilar of Amgens Neupogen Wins U.S. Panel Backing at Bloomberg
01:33PM  When You Should Buy Low Beta Stocks Market Realist
Jan-06-15 12:07PM  UPDATE: Barclays Initiates Coverage On Amgen Benzinga
10:43AM  Will biotech bull run continue? CNBC
Jan-05-15 03:23PM  Amgen announces treatment to compete with Juno, other Seattle biotechs as it exits region at bizjournals.com
02:58PM  Amgen, Kite Pharma team up on immune-based cancer drugs AP
01:13PM  Southern California firms Amgen and Kite team on cancer treatments at Los Angeles Times
12:47PM  FDA Staff Recommends Novartis Biosimilar Version of an Amgen Drug at The Wall Street Journal
12:36PM  [$$] Novartis Wins FDA Staff OK for Neupogen Biosimilar at The Wall Street Journal
12:21PM  Kite Pharma Up On Amgen Cancer Partnership at Investor's Business Daily
10:33AM  Stocks Drop 1% In Rising Volume; Visa Falls 1% at Investor's Business Daily
10:30AM  Amgen, Kite Pharma in Immunotherapy Pact at The Wall Street Journal
10:00AM  Amgen and Kite Pharma in cancer immunotherapy pact at MarketWatch
09:57AM  Amgen, Kite Pharma ink deal to develop cancer immunotherapies Reuters
09:07AM  Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies Benzinga
09:00AM  Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies PR Newswire
Jan-02-15 04:30PM  Biotech investor explains why Juno Therapeutics won't be like Dendreon at bizjournals.com
Dec-26-14 04:16PM  Nasdaq, Russell 2000 Join New-High Party; GoPro Up Again at Investor's Business Daily
03:07PM  Tesla Motors Up On Battery News; Stocks At Record at Investor's Business Daily
Dec-24-14 06:24PM  Biotech Stocks Take A Beating, But Find Support at Investor's Business Daily
04:56PM  Top U.S. Stock Mutual Funds Of 2014: How They Did It at Investor's Business Daily
01:01PM  Are There Any Winners Left In The Biotech Space? Benzinga
Dec-23-14 05:48PM  Buy biotech dip? CNBC
Dec-22-14 09:15AM  Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts PR Newswire
Dec-17-14 05:45PM  Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend PR Newswire
03:11PM  Leaked Sony emails show Loeb influence on studio execs Reuters
01:05PM  Is a Biosimilar (Generic) Top Cancer Drug for You? at 24/7 Wall St.
01:04PM  Amgen Leukemia Treatment to Cost $178,000, Among Priciest Drugs at Bloomberg
12:59PM  Midday Movers: Carnival, Chevron, Netflix & more at CNBC
Dec-15-14 04:44PM  Where is Santa rally? Yahoo Finance Blogs
10:04AM  Is This The Future Of Late-Stage Drug Development? at Forbes
09:34AM  Biotech Entrepreneur Tony Coles Takes Aim At Parkinson's And Alzheimer's at Forbes
Dec-13-14 08:02AM  Meet 5 Top Biotech Stocks Holding Up In Shaky Market at Investor's Business Daily
Dec-11-14 05:38PM  How Can Drugmakers Handle New Pricing Pressures? at Investor's Business Daily
04:01PM  Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1 Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis PR Newswire
03:45PM  bluebird bio (BLUE) Soars on Data from LentiGlobin Study Zacks
06:00AM  How Amgen Makes Billions On Just A Few Drugs at Investopedia
Dec-10-14 05:15PM  Equity markets felland fell hard (no recovery like yesterday) Yahoo Finance Blogs
02:10PM  Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data Zacks
08:16AM  The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan Zacks
Dec-09-14 05:20PM  Dynavax & AstraZeneca Alter Agreement for Asthma Product Zacks
04:00PM  Amgen Successfully Expands Xgeva Label in the U.S. Zacks
08:02AM  Big-Cap Stock Funds Tend To Lag at Investor's Business Daily
Dec-08-14 09:00PM  Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia PR Newswire
06:05PM  Amgen Unveils Positive Results from Blood Cancer Studies Zacks
05:50PM  Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Zacks
04:20PM  New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma PR Newswire
02:17PM  Federal Appeals Court Declines to Address a Crucial Biosimilar Question at The Wall Street Journal
01:12PM  Midday movers: McDonald's, Sony, Celgene & more at CNBC
12:37PM  Celgene CEO: Cancer drug pipeline booming CNBC
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM